Executive Summary

CAR-T cell therapy cures patients with blood cancer. It fails everyone else. Why?

Because every CAR-T cell ever made, since its inception in the 1990s, shares the same overlooked design layer.

VelociTx found it, cracked it, and has filed IP on it.

We've found a novel control layer for CAR-T cells — and we believe it will make them work where they've always died: solid tumors. This isn't a single drug. It's an upgrade the entire CAR-T cell therapy industry could use, and needs.

We're raising $3M to:

1. Show our discovery scales to multiple solid tumor indications and up to 2,000,000 patients in the USA
2. Identify a lead asset for lung cancer, the leading cause of cancer deaths in the USA
3. Expand our IP portfolio to further lock down our coverage of this novel control layer
4. Generate the data package for and sign up our first pharma partnership

CAR-T Cell Therapy Cures Cancer...but Only in the Blood

Chimeric Antigen Receptor (CAR) T cell therapy has produced some of cancer medicine's most dramatic remissions — patients with blood cancers who had exhausted every other option walking out of clinical trials and FDA-approved treatments cancer-free, with decades long remissions now on the books^{1https://www.cancer.gov/about-cancer/treatment/research/car-t-cells }. It is one of the most significant breakthroughs in oncology in a generation^{2https://merkinprize.org/2025-merkin-prize-biomedical-technology-awarded-pioneers-car-t-cell-therapy}.

But here's what the headlines don't say: solid tumors, which represent 90% of all cancer diagnoses, have defeated CAR-T cells. The same approach that cured blood cancers keeps failing against the tumors killing two million Americans every year. Breast cancer. Lung cancer. Pancreatic cancer. Brain cancer. The hostile biology of these tumors overwhelms current CAR-T cell designs before they can do their job.

We all have a personal cancer story, either ourselves or a loved one. Our founder lost his dad to lung cancer in 2025 and is motivated to avenge it.

A >$200B Opportunity, Unlocked by a Single Upgrade

In the early 1990s, scientists assembled the first CAR-T cell — a genetically reprogrammed immune cell designed to seek out cancer, recognize it like a lock and key, and kill it. The invention worked.

Today, that market is worth tens of billions, 50,000 patients have been treated with it, and there’s 100s of clinical trials ongoing. Major pharmaceutical companies have deployed over $55 billion in funding, partnerships, and acquisitions for this space in the past 5 years. It is one of the most active categories in pharmaceutical M&A.

But here is something most people don't know: the core architecture of every approved CAR-T cell therapy still reflects the original biological hypotheses and design choices of the 1990s.

One small, structurally critical piece of the receptor — the part that physically connects the cancer-recognition machinery on the outside of a cell to the killing machinery on the inside of a cell called the transmembrane domain — has been overlooked and under appreciated. In the 30+ year history of CAR-T cell therapy, only three transmembrane domains have ever been used in clinical products. None of them were designed with an intended purpose. They were borrowed from other natural proteins and pasted in.

The transmembrane domain is the overlooked control layer of every CAR-T cell ever made. VelociTx is the first company to engineer it.

Solid tumors are 90% of cancers, and an estimated $200B in market opportunity. In the USA alone, the breast cancer market is >$13B, the lung cancer is >$10B, the pancreatic cancer is >$2B, the brain cancer is $3B. But it's hardly about the money - it's about the hundreds of thousands of patients who need better options.

VelociTx has engineered the control layer for CAR-T cell therapies that our data indicated will unlock solid tumor efficacy.

What VelociTx Found

The transmembrane domain was considered structural scaffolding — the part of the receptor that simply anchors it in the cell membrane. Since the inception of CARs, it was simply accepted as it was.

We didn't believe that. We were right.

VelociTx's data shows the TMD can act as an organizing center — coordinating how the cancer receptor assembles, how signals move through it, and how the cell behaves over time. Change those 22 amino acids, and you change the cell's persistence, its stress tolerance, its ability to keep fighting in the hostile environment of a solid tumor. The TMD isn't inert plumbing.

VelociTx's data shows it is anything but inert.

No one was engineering it. We are.

Our team engineered novel TMD sequences inspired by how the body's natural T cell receptor — the biological machinery that fights cancer without any engineering — assembles and signals. The results were striking:

1. Legacy CAR-T cells burn out under repeated stimulation — the exact hostile conditions inside solid tumors.
2. Cells built with VelociTx TMDs keep growing where legacy CARs die off.
3. We've validated this across multiple experimental conditions, with functional assays, immunophenotyping, and RNA-sequencing all pointing in the same direction.

By changing a small region of the receptor architecture, we are improving CAR-T cell function and long term behavior.

This supports our core thesis: the TMD is not inert. It is a programmable control layer. And no one is thinking about this.

Our goal is to own this new design layer, called our TMDx Engine, for building better CAR-T cells. And we're well on our way.

Because this segment of the protein is small (only 22 amino acids), and the design space for promoting critical assemblies of proteins is limited, we believe we are on our way to locking down this IP space broadly.

VelociTx has filed patent applications covering seven families of novel TMD sequences and their validated sequence motifs. This IP is designed not to protect a single drug, but to protect the design layer — the engineering rules for building better CAR-T cells across any target, any tumor type, any program.

The AI Revolution, Applied to Cancer

The same artificial intelligence revolution that produced ChatGPT is now transforming biology (Anthropic^{3https://www.biospace.com/business/ai-giant-anthropic-leans-into-life-sciences-with-400m-coefficient-bio-catch}, OpenAI^{4https://openai.com/index/gpt-5-lowers-protein-synthesis-cost/}, Nabla^{5https://www.biospace.com/press-releases/nabla-bio-signs-second-takeda-collaboration-to-advance-ai-driven-design-of-protein-therapeutics}, Arc Institute^{6https://arcinstitute.org/}), thanks to Google and DeepMind’s work building AlphaFold^{7https://deepmind.google/science/alphafold/}. Just as AI learned to predict the next word in a sentence by training on billions of human texts, AI can now predict the next amino acid and how it will fold into a protein. In doing so, we can design entirely new proteins that don't exist in nature, based on a user-defined prompt of what they want to build.

VelociTx sees this future and is building it. We use AI-led protein engineering to engineer novel biology, then test it in real immune cells immediately. That wet-lab feedback matters. Biology is too complex to solve on a computer alone.

We are building a loop: Design → Build → Test → Learn → Iterate.

Using a fleet of agentic scientists, we've built our scientific operations around AI. Our agents search the literature nightly, read our lab notebook after every experiment, and synthesize our data against published work — including papers we hadn't found yet.

With local GPU infrastructure, we deploy agents on specific scientific challenges: they read, hypothesize, and run protein design 24/7/365, helping us turn computational predictions into real wet-lab results as fast as possible.

It is 2026. We should not be limited by therapeutic designs discovered in, and unchanged since, the 1990s.

Three Paths to Value Creation

1. Proprietary assets: Develop lead CAR-T programs in-house using the platform's best-performing designs for indications with the strongest unmet need, first targeting lung cancer. Each validated program strengthens the platform's design rules, reduces the cost of future programs, and expands the IP moat. We want to create the best CAR-T cell therapies in the world, and realize the value of those in-house.
2. Platform licensing: License validated TMD design rules to pharmaceutical companies integrating them into existing programs — structured as upfront fees plus milestones plus royalties. Non-dilutive to VelociTx and immediately partnerable once our in vivo data packages are complete from this funding round.
3. Co-development: Partner with pharma on specific tumor indications (lung, prostate, brain tumors, and others — collectively a >$20B addressable market) where VelociTx brings the TMD advantage and the partner brings clinical execution and scale.

Every CAR-T Cell can, and should, be Uplifted with our TMDx Engine

The logic of the VelociTx platform is straightforward:

1. If the TMD is a new design layer for CAR-T and controls important behavior — sensitivity, persistence, functional durability...
2. ...And if VelociTx owns the design rules, motifs, and sequences for engineering better TMDs...
3. ...Then every CAR-T cell program becomes improvable through our platform

This is a platform company — not a single-drug bet. The TMD is a universal design component. It exists in every CAR-T cell ever built. Any company that wants CAR-T cells to work better — in solid tumors, in low-antigen environments, in next-generation allogeneic products — will eventually need VelociTx IP.

Think of it this way: Nvidia doesn't make data centers. Nvidia makes the component that every data center needs. VelociTx is building the equivalent for the CAR-T industry.

Our founding IP and generative biology workflow are designed to make an entire family of next-generation CAR-T cells possible — CARs that are more sensitive, more functional, and better suited to solid tumors than decades old, legacy designs.

Legacy CAR-T cell therapy ignited the field with real cures in blood cancers.

VelociTx is building the next generation: CAR-T cells redesigned for the rest of cancer.

The Market Agrees

The pharmaceutical industry has been signaling the value of cell engineering and AI platforms — loudly — through $55B in acquisition and partnering activity since 2021. We have built an interactive deal room to explore these deals further (https://velocitx.com/partners/).

The Neogene deal is particularly instructive: AstraZeneca paid $320 million for a platform before it had clinical data, because the underlying biology was compelling. VelociTx's TMD platform is pursuing a comparable thesis with comparable potential for early-stage partnership value.

The Round — Up to $500k from Wefunder

We're raising $3M now ($200k closed outside Wefunder), designed to unlock $10M-$20M+ Series A (2027). We're in ongoing fundraising mode with angels and VC, but want to give Wefunder and the base of accredited tech enthusiasts a chance to invest, too.

Use of funds:

1. In vivo validation: Five mouse model studies across multiple solid tumor indications and lead TMD designs — the milestone that converts platform discovery into partner-ready data
2. IP fortification: Expand patent coverage around validated TMD sequence families and design rules
3. Development candidate nomination: Identify the lead asset from the TMD platform for IND-enabling work and Series A positioning
4. Pharma partnering outreach: Initiate licensing and co-development conversations with other CAR-T startups and pharma

The milestone logic is clean: When TMD engineering reproducibly improves CAR-T function in vivo, VelociTx will have evidence of a new, broadly protected design layer for cell therapy.

That evidence triggers multiple financing paths: Series A financing for our own assets, upfront licensing fees, co-development deals, or partnership access fees with pharma.

Our Ultimate Vision

Legacy biology from the 1990s should not govern how well therapeutics work in 2026.

Using protein engineering and our gene editing platform for screening de novo variants at scale, we envision completely redesigning CAR-T cell therapy from the ground up.

We've modified just 22 amino acids of a CAR, roughly 5% of its sequence, and are already seeing a dramatic enhancement. Imagine what will happen when we design, from first principles, the rest of the CAR?

We're accelerating to this future.

Join us.